@article{fdi:010066113,
  title = {{M}alaria burden and anti-malarial drug efficacy in {O}wando, northern {C}ongo},
  author = {{S}ingana, {B}. {P}. and {B}ogreau, {H}. and {M}atondo, {B}. {D}. and {D}ossou-{Y}ovo, {L}. {R}. and {C}asimiro, {P}. {N}. and {M}bouka, {R}. and {N}guyen, {K}. {Y}. {H}. and {P}radines, {B}. and {B}asco, {L}eonardo and {N}dounga, {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {I}n the {R}epublic of {C}ongo, previous epidemiological studies have only been conducted in the south of the country where it is most accessible. {N}ationally representative data on the efficacy of new anti-malarial tools are lacking in the country. {A}s an initial step to close the gap, clinical efficacy of two artemisinin-based combinations, artesunate-amodiaquine ({ASAQ}) and artemether-lumefantrine ({AL}), was assessed in {O}wando, a city in equatorial flooded forest in northern {R}epublic of {C}ongo. {M}ethods: {U}nder 12 years old febrile children attending public health facilities were screened for malaria parasites using lactate dehydrogenase ({LDH})-based rapid diagnostic test ({RDT}) for malaria and microscopic examination of thick blood films. {P}atients with at least 1,000 asexual {P}lasmodium falciparum parasites/mu l of blood were clinically examined, included after informed consent, and followed up for 28 days, according to the 2009 {W}orld {H}ealth {O}rganization protocol. {P}atients were randomly assigned to co-formulated {ASAQ} ({C}oarsucam(({R}))) or {AL} ({C}oartem(({R}))) treatment groups. {P}lasmodium falciparum recrudescent isolates were compared to pre-treatment isolates by polymerase chain reaction ({PCR}) using msp1, msp2, and glurp genes to distinguish between re-infection and recrudescence. {R}esults: {B}etween {N}ovember 2012 and {F}ebruary 2013, 857 under 12 years old febrile children were screened, of whom 198 (23.1 %) had positive {RDT} and 167 (19.5 %) positive thick films. {ASAQ} and {AL} efficacies were 92.7 and 94.2 % before {PCR} correction, respectively. {A}fter genotyping, the overall efficacy was 100 % for {ASAQ} and 98.0 % for {AL}. {C}onclusion: {T}he data reported here represent partially the burden of malaria in 0-11 years old febrile children examined in public health centres of {O}wando city and serve as reference for further studies. {B}oth artemisinin-based combinations were highly efficacious in patients under 12 years old with acute uncomplicated malaria. {ASAQ} was associated with more adverse events, which may reduce compliance in unsupervised treatment.},
  keywords = {{M}alaria ; {P}lasmodium falciparum ; {A}nti-malarial drug ; {D}rug resistance ; {M}icroscopy ; {R}apid diagnostic test ; {A}rtemisinin ; {C}ombination therapy ; {C}ongo-{B}razzaville ; {CONGO}},
  booktitle = {},
  journal = {{M}alaria {J}ournal},
  volume = {15},
  numero = {},
  pages = {art. 16 [10 p.]},
  ISSN = {1475-2875},
  year = {2016},
  DOI = {10.1186/s12936-015-1078-4},
  URL = {https://www.documentation.ird.fr/hor/fdi:010066113},
}